<p><strong>Immune-Mediated Adverse Reactions</strong>:</p>

<ul>
	<li>Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis and hepatotoxicity, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, and immune-mediated nephritis and renal dysfunction.</li>
	<li>Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.</li>
	<li>Withhold or permanently discontinue based on severity and type of reaction.</li>
</ul>

<p><strong>Infusion-related reactions</strong>: Interrupt, slow the rate of infusion, or permanently discontinue Nivolumab based on severity of reaction.<br />
<br />
<strong>Complications of allogeneic HSCT</strong>: Fatal and other serious complications can occur in patient who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody.<br />
<br />
<strong>Embryo-Fetal toxicity</strong>: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.</p>